This study is looking at whether using a smartwatch to track activity and body composition, along with exercise guidance, can help people maintain or build muscle while taking incretin therapy (like liraglutide, semaglutide, tirzepatide, or retatrutide). These medications are often used for obesity. We want to see if this approach can safely improve strength and muscle mass. You could join if you are 18 to 99 years old and have recently started, or are planning to start, one of these incretin therapies within the last two months. The main goal is to measure changes in lean muscle mass after 6 months.

Study design

This interventional study plans to enroll 100 participants. It is not specified if it is randomized or blinded.

What's involved

Participants will be given a smartwatch to monitor exercise and body composition, and will receive general guidance on recommended exercise.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 6 months, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.